John Hancock Life v. Abbott Laboratories

CourtCourt of Appeals for the First Circuit
DecidedNovember 8, 2006
Docket05-2710
StatusPublished

This text of John Hancock Life v. Abbott Laboratories (John Hancock Life v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
John Hancock Life v. Abbott Laboratories, (1st Cir. 2006).

Opinion

United States Court of Appeals For the First Circuit No. 05-2710

JOHN HANCOCK LIFE INSURANCE COMPANY; JOHN HANCOCK VARIABLE LIFE INSURANCE COMPANY; and INVESTORS PARTNER LIFE INSURANCE COMPANY,

Plaintiffs, Appellees,

v.

ABBOTT LABORATORIES,

Defendant, Appellant;

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT MASSACHUSETTS

[Hon. Douglas P. Woodlock, U.S. District Judge]

Before

Torruella and Lipez, Circuit Judges and Stafford,* District Judge.

Lawrence R. Desideri, with whom Stephen V. D'Amore, Peter E. Gelehaar, Michael S. D'Orsi, Winston & Strawn, LLP, and Donnelly, Conroy & Gelharr LLP were on brief, for the appellant. Brian A. Davis, with whom Joseph H. Zwicker, Stacy Blasberg, and Choate, Hall & Stewart LLP were on brief, for the appellee.

September 28, 2006

AMENDED OPINION**

* Of the Northern District of Florida, sitting by designation. ** This opinion has been amended solely to comport with sealing orders issued by the district court and this court. The amendments do not in any way affect the substance of the opinion. LIPEZ, Circuit Judge. John Hancock Life Insurance

Company and two of its subsidiaries (collectively "Hancock")

contracted with Abbott Laboratories ("Abbott") to join in financing

the development of some pharmaceutical compounds. In exchange,

Abbott promised to share with Hancock any profits the compounds

would generate. It soon became apparent that a number of the

compounds had no good prospect of commercial success. Abbott

scaled back and delayed its planned investment in the joint

project. Arguing that Abbott had failed to uphold its part of the

bargain, Hancock stopped contributing funds altogether. Hancock

then sued for a declaratory judgment, asking the district court to

rule that, under the contract between the parties, Abbott's delayed

investment allowed Hancock to terminate its payments but retain its

share of any future profits. Abbott countersued, arguing that the

contract explicitly allowed it to delay its contributions to the

project. The parties consented to have the district court decide

the case on the papers submitted, and, on cross motions, the

district court entered judgment for Hancock. Abbott appeals,

essentially arguing that the district court incorrectly construed

the contract. We affirm.

I.

We discuss the contract between Hancock and Abbott and then

their course of dealings. We leave some details for discussion in

connection with Abbott's appellate arguments.

-2- A. The contract

In 1999, Hancock and Abbott began negotiating the joint

venture at issue. While the specifics evolved through 40 contract

drafts, the basics of the final agreement are relatively simple.

Abbott and Hancock would select a "basket" of research compounds

that Abbott had identified as possible pharmaceutical products and

that Hancock thought were promising. Hancock would contribute

multiple millions each year for four consecutive years towards the

development of these compounds. Abbott would spend at least 1.86

times as much as Hancock over this initial period of development.

The parties would share any profits from the compounds for roughly

fifteen years from the contract's inception, and Abbott would pay

Hancock set amounts when the joint project accomplished certain

development or regulatory goals. In short, Hancock agreed to

provide substantial start-up investment for the project, and Abbott

agreed to match that investment. Because Hancock would share

profits only for a set number of years, it stood to gain if the

compounds were developed quickly (and if they turned out to be

useful) and stood to lose if development were delayed (or if the

compounds were unsuccessful).

For our purposes, the final contract between the parties,

which was signed on March 13, 2001, can be summarized.

! The parties agreed to partner in the development of a basket of compounds, with each compound thought to have a potential pharmaceutical use.

-3- ! Hancock agreed to reimburse multiple millions of Abbott's spending on the joint project in four multiple million dollar payments – one for each year 2001 through 2004.

! Abbott agreed to provide an additional annual minimum contribution of un-reimbursed funds to the project in each of the four years.

! Abbott also agreed that its and Hancock's combined spending on the project would be "at least" the Aggregate Spending Target over the "Program Term," which the contract defined as "a period of four (4) consecutive Program Years."1 In other words, by December 31, 2004, Abbott would provide approximately two-thirds of the Aggregate Spending Target to the project above and beyond the one-third of the Aggregate Spending Target that Hancock promised to contribute.

! Abbott was "permitted" to "change its funding obligations [] only as follows":

(a) If Abbott expended Hancock's yearly contribution during a "Program Year" but did not contribute its annual minimum contribution of its own un-reimbursed funds, Abbott could "carryover" its obligation to the following year. The balance of Abbott's yearly obligation, termed the "Annual Carryover Amount," would be added to Abbott's minimum contribution for the "subsequent Program Year." If Abbott carried over its contribution, Hancock's obligations for the "subsequent Program Year" would be suspended until Abbott spent the "Annual Carryover Amount."

(b) If Abbott did not spend the entire Aggregate Spending Target "during the Program Term," it could "carryover" the balance to the "subsequent year commencing immediately after

1 The contract defined a "Program Year" as a full calendar year beginning on January 1 and ending on December 31, except that the first "Program Year" would be shortened to begin of the day the contract was signed and to end on December 31, 2001.

-4- the end of the Program Term." If there was such a carryover, the difference between the Aggregate Spending Target and the amount actually spent by the end of the "Program Term" would be called the "Aggregate Carryover Amount."

! Abbott would update Hancock at least yearly about the project, providing an "Annual Research Plan" with a budget for future spending. Abbott would also provide yearly "Status Reports" stating the company's spending on the joint project so far. Hancock's payments were due 30 days after receiving these documents.

! In certain enumerated circumstances, including if Abbott "does not demonstrate in its Annual Research Plan its intent and reasonable expectation" to spend at least the Aggregate Spending Target in joint funds on the project "during the Program Term," Hancock's funding obligations would terminate but the rest of the contract (detailing how the parties would share profits) would remain in effect.

! Even if one of the enumerated terminable events came to pass and Hancock's payment obligations were cancelled, Hancock would still have to pay its contributions for the year in which the terminable event took place.

B. The parties' dealings

Abbott's first "Annual Research Plan" was appended to the

final contract, which was executed on March 13, 2001. It called

for total project spending almost double the Aggregate Spending

Target by the end of 2004. Under this plan, Abbott would spend

many millions of dollars of its own funds, or roughly five times as

much as Hancock, through the end of 2004. During 2001, Abbott

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cochran v. Quest Software, Inc.
328 F.3d 1 (First Circuit, 2003)
In Re Blinds to Go Share Purchase Litigation
443 F.3d 1 (First Circuit, 2006)
In Re Support of Halas
470 N.E.2d 960 (Illinois Supreme Court, 1984)
Connecticut Specialty Insurance v. Loop Paper Recycling, Inc.
824 N.E.2d 1125 (Appellate Court of Illinois, 2005)
Krilich v. American National Bank & Trust Co.
778 N.E.2d 1153 (Appellate Court of Illinois, 2002)
Geddes v. Mill Creek Country Club, Inc.
751 N.E.2d 1150 (Illinois Supreme Court, 2001)
Geier v. Hamer Enterprises, Inc.
589 N.E.2d 711 (Appellate Court of Illinois, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
John Hancock Life v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/john-hancock-life-v-abbott-laboratories-ca1-2006.